Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Greenwood Capital Associates LLC

Key Points

• Greenwood Capital Associates LLC cut its stake in Teva by 12.9% in Q4, selling 47,956 shares and now holding 322,480 shares worth about $10.07 million, making TEVA ~1.1% of its portfolio and its 19th-largest position.
• CEO Richard D. Francis sold 442,935 shares on March 3 at an average price of $32.36 for roughly $14.33 million, part of insider sales totaling 920,901 shares (~$30.06 million) over the past 90 days; company insiders now own 0.54% of TEVA.
• Wall Street is broadly positive with a consensus rating of "Moderate Buy" and an average target of $38.78 after several price-target increases, and Teva beat Q4 estimates (EPS $0.96 vs. $0.65; revenue $4.71B vs. $4.36B) while issuing FY2026 guidance of 2.570–2.770 EPS.

Greenwood Capital Associates LLC lowered its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 12.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 322,480 shares of the company's stock after selling 47,956 shares during the period. Teva Pharmaceutical Industries comprises approximately 1.1% of Greenwood Capital Associates LLC's investment portfolio, making the stock its 19th biggest position. Greenwood Capital Associates LLC's holdings in Teva Pharmaceutical Industries were worth $10,065,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. United Advisor Group LLC raised its position in shares of Teva Pharmaceutical Industries by 9.3% in the fourth quarter. United Advisor Group LLC now owns 17,600 shares of the company's stock worth $549,000 after acquiring an additional 1,500 shares during the period. CWM LLC raised its position in shares of Teva Pharmaceutical Industries by 39.2% in the fourth quarter. CWM LLC now owns 7,462 shares of the company's stock worth $233,000 after acquiring an additional 2,101 shares during the period. Farther Finance Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 31.4% in the fourth quarter. Farther Finance Advisors LLC now owns 9,684 shares of the company's stock worth $302,000 after acquiring an additional 2,313 shares during the period. Assetmark Inc. raised its position in shares of Teva Pharmaceutical Industries by 50.1% in the fourth quarter. Assetmark Inc. now owns 55,620 shares of the company's stock worth $1,736,000 after acquiring an additional 18,566 shares during the period. Finally, Choreo LLC acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth about $312,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Activity

In related news, CEO Richard D. Francis sold 442,935 shares of the company's stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the completion of the sale, the chief executive officer owned 642,099 shares of the company's stock, valued at approximately $20,778,323.64. This represents a 40.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard Daniell sold 17,295 shares of the company's stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $547,732.65. Following the sale, the executive vice president directly owned 85,755 shares of the company's stock, valued at approximately $2,715,860.85. This represents a 16.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 920,901 shares of company stock worth $30,056,789. Company insiders own 0.54% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TEVA. Piper Sandler reiterated an "overweight" rating and issued a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. Truist Financial upped their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a "buy" rating in a research report on Wednesday, February 18th. Jefferies Financial Group upped their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday, January 6th. The Goldman Sachs Group upped their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 31st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $38.78.

Teva Pharmaceutical Industries Stock Down 0.5%

TEVA opened at $31.61 on Thursday. Teva Pharmaceutical Industries Ltd. has a twelve month low of $13.04 and a twelve month high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The company has a 50-day moving average price of $31.63 and a 200 day moving average price of $28.46. The company has a market cap of $36.35 billion, a PE ratio of 26.34, a price-to-earnings-growth ratio of 2.77 and a beta of 0.76.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the prior year, the firm earned $0.71 EPS. The company's revenue for the quarter was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.